EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections

María Velasco-de-Andrés, Cristina Català, Laura Carrillo-Serradell, Violeta Planells-Romeo, Lucía Aragón-Serrano, Marta Español-Rego, Lorena Pérez-Amill, Pedro Puerta-Alcalde, Carolina García-Vidal, Manel Juan, Beatriz Martín-Antonio, Francisco Lozano

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.09.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von María Velasco-de-Andrés und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain. Electronic address: mvelascod@recerca.clinic.cat. Hauptthemen laut MEDLINE: Killer Cells, Natural, Receptors, Chimeric Antigen, Invasive Fungal Infections, Adoptive Transfer. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Ciencia e Innovación, European Commission, Government of Spain Ministry of Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of invasive fungal infections (IFIs) poses a major health challenge due to their severity, the scarcity and toxicity of current antifungal drugs, and the emergence of drug-resistant strains, thus forcing the search for novel strategies. Approaches involving adoptive transfer of immune cells harboring chimeric antigen receptors (CARs) are gaining momentum in several clinical settings. Based on the fungal β-glucan-binding properties of the lymphocyte scavenger receptor CD5, we assayed NK and T cells engineered with a CD5-based second-generation CAR (SRCD5CAR) for the treatment of IFI. In vitro results revealed that SRCD5CAR expression specifically potentiates NK cell activation (i.e., CD69 expression and cytokine/chemokine production) and killing (i.e., CD107a expression and perforin/granzyme production) against different pathogenic fungal species (i.e., Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, and Fusarium solani). Further in vivo infusion of SRCD5CAR-NK cells into fungal-infected NSG mice increased survival rates and decreased fungal burden in target organs. Similar in vitro and in vivo antifungal observations were also obtained for SRCD5CAR-T cells. Overall, the superior and specific performance exhibited by SRCD5CAR-transduced NK cells open new avenues for the development of novel off-the-shelf adoptive transfer of allogeneic cells against IFI, be those alone or adjunctive to antifungal drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalReceptors, Chimeric AntigenInvasive Fungal InfectionsAdoptive TransferCD5 AntigensImmunotherapy, AdoptiveAnimalsMiceHumansLymphocyte ActivationDisease Models, Animal

Stichwörter der Autor:innen

CD5NK cellsadoptive cell transferchimeric antigen receptorfungal infection

Substanzen

Receptors, Chimeric AntigenCD5 Antigens

Autor:innen und Institutionen

  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain. Electronic address: mvelascod@recerca.clinic.cat.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
  • Servei d'Immunologia, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
  • Servei d'Immunologia, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; Fundació Clínic per a la Recerca Biomèdica, 08036 Barcelona, Spain; Gyala Therapeutics S.L., 08007 Barcelona, Spain.
  • Servei de Malalties Infeccioses, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Servei d'Immunologia, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; Departament de Biomedicina, Facultat de Medicina, U…

Förderung

  • Ministerio de Ciencia e Innovación
  • European Commission
  • Government of Spain Ministry of Universities
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • European Society of Clinical Microbiology and Infectious Diseases
  • Instituto de Salud Carlos III

Zitieren

APA

Velasco-de-Andrés, M., Català, C., Carrillo-Serradell, L., Planells-Romeo, V., Aragón-Serrano, L., Español-Rego, M., Pérez-Amill, L., Puerta-Alcalde, P., García-Vidal, C., Juan, M., Martín-Antonio, B., & Lozano, F. (2025). Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.09.003

Vancouver

Velasco-de-Andrés M, Català C, Carrillo-Serradell L, Planells-Romeo V, Aragón-Serrano L, Español-Rego M, et al. Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.09.003

BibTeX
@article{VelascodeAndrs2025,
  author = {Velasco-de-Andrés, María and Català, Cristina and Carrillo-Serradell, Laura and Planells-Romeo, Violeta and Aragón-Serrano, Lucía and Español-Rego, Marta and Pérez-Amill, Lorena and Puerta-Alcalde, Pedro and García-Vidal, Carolina and Juan, Manel and Martín-Antonio, Beatriz and Lozano, Francisco},
  title = {Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.09.003}
}
Kostenlos starten →